Play all audios:
ABSTRACT The role of p53 as a central mediator of the DNA damage and other cellular stress responses is well established. The ultimate growth-suppressive function of p53 in part explains its
ability to confer chemosensitivity and radiosensitivity upon tumor cells. Recent work in the field has added complexity to our understanding, in terms of identifying novel regulators of p53
stability and function, elucidation of the importance of the p53 family towards p53 function, a growing list of transcriptional targets as well as transcription-independent apoptotic
effects and mechanisms, tissue specificity of the p53 response, a molecular understanding of p53-dependent therapeutic sensitization, and efforts towards molecular targeting of the p53
pathway. p53 remains an attractive target for drug development in cancer because its alteration provides a fundamental difference between normal and cancer cells. Strategies are emerging for
the identification of mutant p53-specific therapies, therapies targeted at mutant p53-expressing tumors, as well as therapies that target various aspects of the p53 life cycle to enhance
chemosensitization. The tools of molecular imaging are beginning to accelerate the pace of discovery and preclinical testing of p53 in animal models. The future holds promise for specific,
individualized targeting of mutant or wild-type p53, or its transcriptional targets, in combination therapies with other cancer-specific drugs, to maximize tumor cell killing while
protecting normal cells from toxic side effects. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access
through your institution Subscribe to this journal Receive 50 print issues and online access $259.00 per year only $5.18 per issue Learn more Buy this article * Purchase on SpringerLink *
Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional
subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS TARGETING P53 PATHWAYS: MECHANISMS, STRUCTURES AND ADVANCES IN THERAPY Article Open access 01
March 2023 PHARMACOLOGICAL REACTIVATION OF P53 IN THE ERA OF PRECISION ANTICANCER MEDICINE Article 15 December 2023 SELECTIVE THERAPEUTIC STRATEGY FOR P53-DEFICIENT CANCER BY TARGETING
DYSREGULATION IN DNA REPAIR Article Open access 12 July 2021 REFERENCES * Amundson SA, Patterson A, Do KT and Fornace AJ . (2002). _Cancer Biol. Ther._, 1, 145–149. * An WG, Kanekal M, Simon
MC, Maltepe E, Blagosklonny MV and Neckers LM . (1998). _Nature_, 392, 405–408. * Ashcroft M, Taya Y and Vousden KH . (2000). _Mol. Cell. Biol._, 20, 3224–3233. * Badciong JC and Haas AL .
(2002). _J. Biol. Chem._, 277, 49668–49675. * Bakkenist CJ and Kastan MB . (2003). _Nature_, 421, 499–506. * Basu S, Totty NF, Irwin MS, Sudol M and Downward J . (2003). _Mol. Cell_, 11,
11–23. * Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Marlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell
PJ, Smith P, Lu X and Crook T . (2003a). _Cancer Cell_, 3, 387–402. * Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh JK, O'Connor DJ, Zhong S, Campargue I,
Tomlinson ML, Kuwabara PE and Lu X . (2003b). _Nat. Genet._, 33, 162–167. * Blagosklonny MV and El-Deiry WS . (1996). _Int. J. Cancer_, 67, 386–392. * Blagosklonny MV and El-Deiry WS .
(1998). _Int. J. Cancer_, 75, 933–940. * Bottger A, Bottger V, Sparks A, Liu WL, Howard SF and Lane DP . (1997). _Curr. Biol._, 7, 860–869. * Bottger V, Bottger A, Howard SF, Picksley SM,
Chene P, Garcia Echeverria C, Hochkeppel HK and Lane DP . (1996). _Oncogene_, 13, 2141–2147. * Brooks CL and Gu W . (2003). _Curr. Opin. Cell Biol._, 15, 164–171. * Burns TF, Bernhard EJ and
El-Deiry WS . (2001). _Oncogene_, 20, 4601–4612. * Burns TF and El-Deiry WS . (2003). _Cancer Treat Res._, 115, 319–343. * Burns TF, Fei P, Scata KA, Dicker DT and El-Deiry WS . (2003).
_Mol. Cell. Biol._, 23, 5556–5571. * Bykov VJN, Issaeva N, Shilov A, Hulcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G . (2002). _Nat. Med._, 8, 282–288. * Caelles
C, Helmberg A and Karin M . (1994). _Nature_, 370, 220–223. * Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ,
Ratcliffe P, Moons L, Jain RK, Collen D and Keshet E . (1998). _Nature_, 394, 485–490. * Chehab NH, Malikzay A, Stavridi ES and Halazonetis TD . (1999). _Proc. Natl. Acad. Sci. USA_, 96,
13777–13782. * Cho YJ, Gorina S, Jeffrey PD and Pavletich NP . (1994). _Science_, 265, 346–355. * Choi J, Nannenga B, Demidov ON, Bulavin DV, Cooney A, Brayton C, Zhang YX, Mbawuike IN,
Bradley A, Appella E and Donehower LA . (2002). _Mol. Cell. Biol._, 22, 1094–1105. * Deb SP . (2002). _Front Biosci._, 7, D235–D243. * Deng CX, Zhang PM, Harper JW, Elledge SJ and Leder P .
(1995). _Cell_, 82, 675–684. * Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn R, Humm J, Larson S, Sadelain M, Blasberg R and Tjuvajev JG . (2001). _Proc. Natl. Acad.
Sci. USA_, 98, 9300–9305. * Dumaz N, Milne DM and Meek DW . (1999). _FEBS Lett._, 463, 312–316. * Dumont P, Leu JI-J, Della Tietra III AC, George DL and Murphy M . (2003). _Nat. Genet._, 33,
357–365. * El-Deiry WS . (1998). _Semin. Cancer Biol._, 8, 345–357. * El-Deiry WS . (2001). _Cell Death Differ._, 8, 1066–1075. * El-Deiry WS . (2002). _Cancer Biol. Ther._, 1, 490–491. *
El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang YS, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW and
Vogelstein B (1994). _Cancer Res._, 54, 1169–1174. * Fei P, Bernhard EJ and El-Deiry WS . (2002). _Cancer Res._, 62, 7316–7327. * Finch RA, Donoviel DB, Potter D, Shi M, Fan A, Freed DD,
Wang CY, Zambrowicz BP, Ramirez-Solis R, Sands AT and Zhang N . (2002). _Cancer Res._, 62, 3221–3225. * Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F and Jacks T . (2002).
_Nature_, 416, 560–564. * Foster BA, Coffey HA, Morin MJ and Rastinejad F . (1999). _Science_, 286, 2507–2510. * Freeman DJ, Li AG, Wei G, Li H-H, Kertesz N, Lesche R, Whale AD,
Martinez-Diaz H, Rozengurt N, Cardiff RD, Liu X and Wu H . (2003). _Cancer Cell_, 3, 117–130. * Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, Criado LM, Klatt P, Flores JM, Weill JC,
Blasco MA and Serrano M . (2002). _EMBO J._, 21, 6225–6235. * Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H, Nakatani Y and Livingston DM . (2003). _Science_, 300, 342–344. *
Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A, Galanis E, Uprichard M, Omar C, Bycott P, Hackman RC and Shields AF . (2003). _J. Clin. Oncol._, 21, 1498–1504. * Hecht JR, Bedford R,
Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH and Freeman SM . (2003). _Clin. Cancer Res._, 9, 555–561. * Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C,
Hannon GJ and Lowe SW . (2003). _Nat. Genet._, 33, 396–400. * Herbert BS, Pearce VP, Hyman LS, LaRue DM, Wright WE, Kopelovich L and Shay JW . (2003). _Cancer Res._, 63, 1914–1919. * Hirao
A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A, Okada H, Sarkissian T, Wong JA, Sakai T, de Stanchina E, Bristow RG, Suda T, Lowe SW, Jeggo PA, Elledge SJ and Mak TW . (2002). _Mol.
Cell. Biol._, 22, 6521–6532. * Hoffman WH, Biade S, Zilfou JT, Chen JD and Murphy M . (2002). _J. Biol. Chem._, 277, 3247–3257. * Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC and Kaelin WG
. (2003). _Cancer Cell_, 3, 403–410. * Jimenez GS, Nister M, Stommel JM, Beeche M, Barcarse EA, Zhang XQ, O’Gorman S and Wahl GM . (2000). _Nat. Genet._, 26, 37–42. * Kastan MB and Zambetti
GP . (2003). _Cell_, 112, 1–2. * Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV and Gudkov AV . (1999). _Science_, 285, 1733–1737. * Komarova EA, Neznanov N,
Komarov PG, Chernov MV, Wang K and Gudkov AV . (2003). _J. Biol. Chem._, 278, 15465–15468. * Koumenis C, Alarcon R, Hammond D, Sutphin P, Hoffman W, Murphy M, Derr J, Taya Y, Lowe SW,
Kastan M and Giaccia A . (2001). _Mol. Cell. Biol._, 21, 1297–1310. * Laxman B, Hall DE, Bhojani MS, Hamstra DA, Chenevert TL, Ross BD and Rehemtulla A . (2002). _Proc. Natl. Acad. Sci.
USA_, 99, 16551–16555. * Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R and Benchimol S . (2003). _Cell_, 112, 779–791. * Li MY, Chen DL, Shiloh A, Luo JY,
Nikolaev AY, Qin J and Gu W . (2002). _Nature_, 416, 648–653. * Lowe SW and Sherr CJ . (2003). _Curr. Opin. Genet. Dev._, 13, 77–83. * Lowe SW, Ruley HE, Jacks T and Housman DE . (1993).
_Cell_, 74, 957–967. * MacLachlan TK and El-Deiry WS . (2002). _Proc. Natl. Acad. Sci. USA_, 99, 9492–9497. * MacLachlan TK, Takimoto R and El-Deiry WS . (2002). _Mol. Cell. Biol._, 22,
4280–4292. * Manfredi JJ . (2003). _Mol. Cell_, 11, 552–554. * Massoud TF and Gambhir SS . (2003). _Genes Dev._, 17, 545–580. * Maya R, Balass M, Kim ST, Shkedy D, Leal JFM, Shifman O, Moas
M, Buschmann T, Ronai Z, Shiloh Y, Kastan MB, Katzir E and Oren M . (2001). _Genes Dev._, 15, 1067–1077. * Melino G, De Laurenzi V and Vousden KH . (2002). _Nat. Rev. Cancer_, 2, 605–615. *
Michael D and Oren M . (2003). _Semin. Cancer Biol._, 13, 49–58. * Midgley CA, Desterro JMP, Saville MK, Howard S, Sparks A, Hay RT and Lane DP . (2000). _Oncogene_, 19, 2312–2323. * Mihara
M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P and Moll UM . (2003). _Mol. Cell_, 11, 577–590. * Moroni MC, Hickman ES, Denchi EL, Caprara G, Colli E, Cecconi F, Muller H and
Helin K . (2001). _Nat. Cell. Biol._, 3, 552–558. * Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ and George DL . (1999). _Genes Dev._, 13, 2490–2501. * Nikolaev AY, Li MY,
Puskas N, Qin J and Gu W . (2003). _Cell_, 112, 29–40. * Nishizaki M, Meyn RE, Levy LB, Atkinson EN, White RA, Roth JA and Ji L . (2001). _Clin. Cancer Res._, 7, 2887–2897. * O'Connor
PM, Jackman J, Bae I, Myers TG, Fan SJ, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ and Kohn KW . (1997). _Cancer Res._, 57, 4285–4300. * Oda E, Ohki R,
Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T and Tanaka N . (2000). _Science_, 288, 1053–1058. * Ollmann M, Young LM, Di Como CJ, Karim F, Belvin M, Robertson S,
Whittaker K, Demsky M, Fisher WW, Buchman A, Duyk J, Friedman L, Prives C and Kopczynski C . (2000). _Cell_, 101, 91–101. * Peng Y, Li C, Chen L, Sebti S and Chen J . (2003). _Oncogene_, 22,
4478–4487. * Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B . (1997). _Nature_, 389, 300–305. * Rippin TM, Bykov VJN, Freund SMV, Selivanova G, Wiman KG and Fersht AR . (2002).
_Oncogene_, 21, 2119–2129. * Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T and Lu X . (2001). _Mol. Cell_, 8, 781–794. *
Sax JK and El-Deiry WS . (2003). _Cell Death Differ._, 10, 413–417. * Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ and El-Deiry WS . (2002). _Nat. Cell. Biol._, 4, 842–849. * Schmitt
CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM and Lowe SW . (2002). _Cell_, 109, 335–346. * Slee EA and Lu X . (2003). _Toxicol. Lett._, 139, 81–87. * Soengas MS, Capodieci P, Polsky
D, Mora J, Estellar M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C and Lowe SW . (2001). _Nature_, 409, 207–211. * Song E, Lee S-K, Wang J, Ince N, Ouyang N,
Min J, Chen J, Shankar P and Lieberman J . (2003). _Nat. Med._, 9, 347–351. * Soussi T . (2003). _Cancer Cell_, 3, 303–305. * Takimoto R and El-Deiry WS . (2000). _Oncogene_, 19, 1735–1743.
* Takimoto R, MacLachlan TK, Dicker DT, Niitsu Y, Mori T and El-Deiry WS . (2002a). _Cancer Biol. Ther._, 1, 177–186. * Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J and
El-Deiry WS . (2002b). _Cancer Biol. Ther._, 1, 47–55. * Tan T and Chu G . (2002). _Mol. Cell. Biol._, 22, 3247–3254. * Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K,
Takei Y and Nakamura Y . (2000). _Nature_, 404, 42–49. * Tanikawa C, Matsuda K, Fukuda S, Nakamura Y and Arakawa H . (2003). _Nat. Cell. Biol._, 5, 216–223. * Velculescu VE and El-Deiry WS .
(1996). _Clin. Chem._, 42, 858–868. * Vogelstein B and Kinzler KW . (1992). _Cell_, 70, 523–526. * Vogelstein B, Lane D and Levine AJ . (2000). _Nature_, 408, 307–310. * Vousden KH .
(2000). _Cell_, 103, 691–694. * Vousden KH and Lu X . (2002). _Nat. Rev. Cancer_, 2, 594–604. * Waldman T, Zhang YG, Dillehay L, Yu J, Kinzler K, Vogelstein B and Williams J . (1997). _Nat.
Med._, 3, 1034–1036. * Walker KK and Levine AJ . (1996). _Proc. Natl. Acad. Sci. USA_, 93, 15335–15340. * Wang W and El-Deiry WS . (2003). _Cancer Biol. Ther._, 2, 196–202. * Wang W,
Takimoto R, Rastinejad F and El-Deiry WS . (2003). _Mol. Cell. Biol._, 23, 2171–2181. * Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB
and Korsmeyer SJ . (2001). _Science_, 292, 727–730. * Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK,
vanOsdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE and Paull KD . (1997). _Science_, 275, 343–349. * Wu GS and El-Deiry WS .
(1996). _Clin. Cancer Res._, 2, 623–633. * Yin YX, Liu YX, Jin YJ, Hall EJ and Barrett JC . (2003). _Nature_, 422, 527–531. * Yu J, Wang ZH, Kinzler KW, Vogelstein B and Zhang L . (2003).
_Proc. Natl. Acad. Sci. USA_, 100, 1931–1936. * Zhou BHP and Hung MC . (2002). _Semin. Oncol._, 29, 62–70. * Zhou BHP, Liao Y, Xia WY, Zou YY, Spohn B and Hung MC . (2001). _Nat. Cell.
Biol._, 3, 973–982. Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Departments of Medicine (Hematology/Oncology), Genetics, Pharmacology, Abramson Cancer Center,
University of Pennsylvania School of Medicine, Philadelphia, PA, USA Wafik S El-Deiry Authors * Wafik S El-Deiry View author publications You can also search for this author inPubMed Google
Scholar CORRESPONDING AUTHOR Correspondence to Wafik S El-Deiry. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE El-Deiry, W. The role of p53 in
chemosensitivity and radiosensitivity. _Oncogene_ 22, 7486–7495 (2003). https://doi.org/10.1038/sj.onc.1206949 Download citation * Published: 23 October 2003 * Issue Date: 20 October 2003 *
DOI: https://doi.org/10.1038/sj.onc.1206949 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not
currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * p53 * apoptosis * cancer * chemotherapy * tissue
specificity * CP-31398 * Prima1 * MDM2 * p73 * Parc * Pirh2 * HAUSP * ASPP1 * BRCA1 * PAC1 * p300 * ONYX-015 * toxicity * stability * transcription